Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith
  
Generate a summary of this article
Listen to this article
Beta

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

scale with globe on one side and a business man holding onto a circle graph divided into sections on the other.
FDA Commissioner called for rebalancing of US pharma supply chains to decrease reliance on China, without eliminating relationship. (Shutter)

The US needs a more diversified pharmaceutical supply chain, FDA Commissioner Robert Califf said, but the handling of that transition may need to be more delicate than current policy proposals are designed to accomplish, his remarks indicated.

Key Takeaways

  • FDA Commissioner Robert Califf stressed the US’s need for a more diversified drug supply chain that is less reliant on China, but cautioned against taking action that is too extreme given the two countries’ interconnectedness.

Almost 100% of the key starting materials for pharmaceuticals used in the US come from China, creating a supply chain...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Distribution/Supply Chain

Akash test for clone

 
• By akash

Test article to check the clone issue

Califf: Not Wise To Create Problems Related to Chinese Pharma Supply Chain Dependence

 
• By Sarah Karlin-Smith

The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.

French Fine 11 Firms For Failure To Meet Stock Obligations

 
• By Ian Schofield

A total of 748 key medicines are now affected by the four-month stock requirement, compared with 422 in 2021.

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 
• By Eliza Slawther

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

More from North America

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By Sue Sutter

Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.

New US FDA Adcomm Trend: Approved Cancer Meds Get Another Look When Competitors Coming

 
• By Sarah Karlin-Smith

Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.